Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis.

MLA

Binder, Nikolaus B., et al. “Tumor Necrosis Factor-Inhibiting Therapy Preferentially Targets Bone Destruction but Not Synovial Inflammation in a Tumor Necrosis Factor-Driven Model of Rheumatoid Arthritis.” Arthritis & Rheumatism, vol. 65, no. 3, Mar. 2013, pp. 608–17. EBSCOhost, https://doi.org/10.1002/art.37797.

APA

Binder, N. B., Puchner, A., Niederreiter, B., Hayer, S., Leiss, H., Blüml, S., Kreindl, R., Smolen, J. S., & Redlich, K. (2013). Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. Arthritis & Rheumatism, 65(3), 608–617. https://doi.org/10.1002/art.37797

Chicago

Binder, Nikolaus B., Antonia Puchner, Birgit Niederreiter, Silvia Hayer, Harald Leiss, Stephan Blüml, Roman Kreindl, Josef S. Smolen, and Kurt Redlich. 2013. “Tumor Necrosis Factor-Inhibiting Therapy Preferentially Targets Bone Destruction but Not Synovial Inflammation in a Tumor Necrosis Factor-Driven Model of Rheumatoid Arthritis.” Arthritis & Rheumatism 65 (3): 608–17. doi:10.1002/art.37797.